ArticleOPEN ACCESS

Duchenne muscular dystrophy: CRISPR/Cas9 treatment

Cell Research
DOI: 10.1038/cr.2016.28
46Citations
Citations of this article
186Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A novel approach to gene correction by genome editing shows great promise as a treatment for Duchenne muscular dystrophy (DMD). CRISPR/Cas9 delivered by adeno-associated virus to a mouse model for DMD demonstrated improvement in function and histology.

Cite

CITATION STYLE

APA

Mendell, J. R., & Rodino-Klapac, L. R. (2016, May 1). Duchenne muscular dystrophy: CRISPR/Cas9 treatment. Cell Research. Nature Publishing Group. https://doi.org/10.1038/cr.2016.28

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free